MET and non-small cell lung carcinoma: Amplification of c-MET, a transmembrane tyrosine kinase receptor, can already occur before the treatment with TKIs in NSCLC [32], [33], [34], [35], and c-MET is expressed in 60% of NSCLC tumors as measured by immunohistochemistry [34].